

# Monica Furlano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7672125/publications.pdf>

Version: 2024-02-01

15  
papers

392  
citations

1040056

9  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

509  
citing authors

#	ARTICLE	IF	CITATIONS
1	A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases. <i>Kidney International</i> , 2018, 94, 363-371.	5.2	109
2	Clinical and Genetic Features of Autosomal Dominant Alport Syndrome: A Cohort Study. <i>American Journal of Kidney Diseases</i> , 2021, 78, 560-570.e1.	1.9	48
3	Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 687-696.	0.7	44
4	Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1. <i>American Journal of Kidney Diseases</i> , 2018, 72, 411-418.	1.9	42
5	New therapeutic options for Alport syndrome. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1272-1279.	0.7	37
6	Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1879-1885.	2.9	36
7	Novel homozygous OSGEP gene pathogenic variants in two unrelated patients with Galloway-Mowat syndrome: case report and review of the literature. <i>BMC Nephrology</i> , 2019, 20, 126.	1.8	16
8	Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression. <i>American Journal of Nephrology</i> , 2018, 48, 308-317.	3.1	15
9	Generation of integration-free induced pluripotent stem cell lines derived from two patients with X-linked Alport syndrome (XLAS). <i>Stem Cell Research</i> , 2017, 25, 291-295.	0.7	13
10	Treatment and long-term outcome in primary nephrogenic diabetes insipidus. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 2120-2130.	0.7	9
11	Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport syndrome (ARAS). <i>Stem Cell Research</i> , 2017, 25, 1-5.	0.7	8
12	Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 912-921.	2.9	5
13	How genomics reclassifies diseases: the case of Alport syndrome. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 933-935.	2.9	4
14	Autosomal dominant polycystic kidney disease: possibly the least silent cause of chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2281-2284.	2.9	3
15	Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2063-2071.	2.9	3